BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: López-Sánchez LM, Mena R, Guil-Luna S, Mantrana A, Peñarando J, Toledano-Fonseca M, Conde F, De la Haba-Rodríguez JR, Aranda E, Rodríguez-Ariza A. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells. Lab Invest 2021;101:292-303. [PMID: 33262438 DOI: 10.1038/s41374-020-00507-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Yoon B, Dey A, Nguyen VQ, Park JH. Recent progress in nitric oxide-generating nanomedicine for cancer therapy. J Control Release 2022;352:179-98. [PMID: 36228954 DOI: 10.1016/j.jconrel.2022.10.012] [Reference Citation Analysis]
2 Lin K, Baritaki S, Vivarelli S, Falzone L, Scalisi A, Libra M, Bonavida B. The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. Antioxidants (Basel) 2022;11:1195. [PMID: 35740092 DOI: 10.3390/antiox11061195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hu X, Gao X, Gao G, Wang Y, Cao H, Li D, Hua H. Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents. Bioorganic & Medicinal Chemistry Letters 2021;40:127952. [DOI: 10.1016/j.bmcl.2021.127952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]